Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Norodisk caps insulin prices at $35 for Minnesotans
Now Novo Nordisk is required to provide insulin products at $35 per monthly prescription for customers paying with cash. The settlement also requires all three companies to use a texting system to raise awareness of low-cost insulin options, according to the press release.
Minnesota AG announces insulin settlement
ST. PAUL, Minn. – Minnesota Attorney General Keith Ellison settled with insulin manufacturers Eli Lilly, Sanofi, and Novo Nordisk, guaranteeing that Minnesotans can purchase a month’s supply of Eli Lilly and Sanofi insulin products for just $35 for the next 5 years.
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American ...
Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it ...
Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%. Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial ...
9d
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.
2don MSN
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Luxury fashion house LVMH has reclaimed its title as Europe’s most valuable company from Novo Nordisk, as early signs of a luxury comeback coincided with fresh struggles for the Danish Ozempic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback